Background: Hepatocellular carcinoma is the 2nd leading cause of cancer death among Chinese residents. Patients with cancer simultaneously experience multiple symptoms. Most of the current studies on patients with advanced hepatocellular carcinoma focus on the treatment effect, or focus on a single symptom, with less attention to the management of symptom clusters in patients. Objectives: The aim of this research is to explore the symptom experience of hepatocellular carcinoma patients after hepatic arterial infusion chemotherapy surgery and the Relationship between each symptom experience and total number of patient symptoms. Methods: A symptom Assessment Questionnaire for Patients undergoing Hepatic Arterial Infusion Chemotherapy (HAIC) was administered to a sample of 278 patients with hepatocellular carcinoma at advanced stages. Data were analyzed using descriptive statistics, Pearson correlation, and regression analyses. Results: The most striking result to emerge from the data is that the most severe symptoms in patients after HAIC surgery were Poor sleep and Decreased appetite. And presence of psychological suffering, pain, gastrointestinal discomfort, and bad mood may cause patients to develop more symptoms. Conclusions: Patients with hepatoma after HAIC surgery concurrently experienced multiple symptoms of discomfort. We should pay more attention to the symptomatic experience of these patients. A further study with more focus on the management of the most common and comorbid multiple symptoms to reduce symptoms and improve quality of life in patients with hepatocellular carcinoma is therefore suggested.
| Published in | Cancer Research Journal (Volume 11, Issue 4) |
| DOI | 10.11648/j.crj.20231104.13 |
| Page(s) | 136-141 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
Hepatic Arterial Infusion Chemotherapy, Hepatocellular Carcinoma, Symptom Experience
| [1] | Xia C, Dong X, Li H, Cao M, Sun D, et al. 2022. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chinese Med. J.-Peking 135: 584-90. DOI: 10.1097/CM9.0000000000002108. |
| [2] | Tan, D. J. H. Setiawan, V. W. Ng, C. H. Lim, W. H. Muthiah, M. D. Tan, E. X. Dan, Y. Y. Roberts, L. R. Loomba, R. Huang, D. Q. Global burden of liver cancer in males and females: Changing etiological basis and the growing contribution of NASH. [J] Hepatology. 2023 Apr 1; 77(4): 1150-1163. doi: 10.1002/hep.32758. Epub 2022 Sep 12. |
| [3] | Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019 Oct; 16(10): 589-604. doi: 10.1038/s41575-019-0186-y. |
| [4] | Sidaway, P., HAIC-FO improves outcomes in HCC. Nature Reviews Clinical Oncology, 2022. 19(3): p. 150-150. DOI: 10.1038/s41571-022-00599-0. |
| [5] | Lyu, Ning, Wang; XunLi, Ji-BinLai, Jin-FaChen, Qi-Feng, Li, Shao-Long, Deng, Hai-Jing; He, Meng; Mu, Lu-Wen; Zhao, Ming. Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1). [J]. Journal of Clinical Oncology. 2021. 40(5): p. 468-480. DOI: 10.1200/JCO.21.01963. |
| [6] | Chen LT, Martinelli E, Cheng AL, et al: Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: A TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Ann Oncol. 2020 Mar; 31(3): 334-351. doi: 10.1016/j.annonc.2019.12.001. Epub 2019 Dec 20. |
| [7] | Wang, T., et al., Efficacy and safety of hepatic artery infusion chemotherapy with mFOLFOX in primary liver cancer patients with hyperbilirubinemia and ineffective drainage: a retrospective cohort study. Annals of Translational Medicine, 2022. 10(7): p. 411-411. DOI: 10.21037/atm-22-978. |
| [8] | Bruix, J., et al., Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference. Journal of Hepatology, 2001. 35(3): p. 421-430. DOI: https://doi.org/10.1016/S0168-8278(01)00130-1 |
| [9] | Chung, M., S. Wang and C. Lin, Symptom Clusters and Impact of Fatigue and Sleep Disturbance on Symptom Experiences of Hepatoma Patients in Taiwan. Cancer Nursing, 2017. 40(5): p. 403-411. DOI: 10.1097/NCC.0000000000000417. |
| [10] | Dodd MJ, Miaskowski C, Paul SM. Symptom clusters and their effect on the functional status of patients with cancer. Oncol Nurs Forum. 2001 Apr; 28(3): 465-70. PMID: 11338755. |
| [11] | Kim HJ, McGuire DB, Tulman L, et al. Symptom clusters: concept analysis and clinical implications for cancer nursing. Cancer Nurs 2005; 28: 270–282. |
| [12] | Lyu, N., et al., Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin in Hepatocellular Cancer with Extrahepatic Spread. Journal of Vascular and Interventional Radiology, 2019. 30(3): p. 349-357.e2. DOI: 10.1016/j.jvir.2018.09.004. |
| [13] | Park, J. W., et al., Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int, 2015. 35(9): p. 2155-66. DOI: 10.1111/liv.12818. |
| [14] | Aktas, A., D. Walsh and L. Rybicki, Symptom clusters and prognosis in advanced cancer. Supportive Care in Cancer, 2012. 20(11): p. 2837-2843. DOI: 10.1007/s00520-012-1408-9. |
| [15] | Punjabi, N. M. Caffo, B. S. Goodwin, J. L. Sleep-disordered breathing and mortality: a prospective cohort study [J]. PLoS Med. 2009 Aug; 6(8): e1000132. doi: 10.1371/journal.pmed.1000132. Epub 2009 Aug 18. |
| [16] | Chung, M. H., S. Y. Wang and C. C. Lin, Symptom Clusters and Impact of Fatigue and Sleep Disturbance on Symptom Experiences of Hepatoma Patients in Taiwan. Cancer Nurs, 2017. 40(5): p. 403-411. doi: 10.1097/NCC.0000000000000417. |
| [17] | Golan-Vered Y, Pud D. Chemotherapy-induced neuropathic pain and its relation to cluster symptoms in breast cancer patients treated with paclitaxel. Pain Prac 2013; 13: 46–52. DOI: https://doi.org/10.1111/j.1533-2500.2012.00554.x. |
| [18] | Esther Kim, J., et al., A Review of the Prevalence and Impact of Multiple Symptoms in Oncology Patients. Journal of Pain and Symptom Management, 2009. 37(4): p. 715-736. DOI: 10.1016/j.jpainsymman.2008.04.018. |
| [19] | Bruyneel, M. and T. Serste, Sleep disturbances in patients with liver cirrhosis: prevalence, impact, and management challenges. 2018. Volume 10: p. 369-375. DOI: 10.2147/NSS.S186665. |
| [20] | Graf, J. and A. Stengel, Psychological Burden and Psycho-Oncological Interventions for Patients With Hepatobiliary Cancers–A Systematic Review. Frontiers in Psychology, 2021. 12. DOI: 10.3389/fpsyg.2021.662777. |
| [21] | Kaiser, K., et al., Important and relevant symptoms including pain concerns in hepatocellular carcinoma (HCC): a patient interview study. Supportive Care in Cancer, 2014. 22(4): p. 919-926. DOI: 10.1007/s00520-013-2039-5. |
| [22] | Christian-Miller, N. and C. Frenette, Hepatocellular cancer pain: impact and management challenges. 2018. Volume 5: p. 75-80. DOI: 10.2147/JHC.S145450. |
APA Style
Juan, D. (2023). A Study of Symptom Experience of Hepatocellular Carcinoma Patients After Hepatic Arterial Infusion Chemotherapy Surgery. Cancer Research Journal, 11(4), 136-141. https://doi.org/10.11648/j.crj.20231104.13
ACS Style
Juan, D. A Study of Symptom Experience of Hepatocellular Carcinoma Patients After Hepatic Arterial Infusion Chemotherapy Surgery. Cancer Res. J. 2023, 11(4), 136-141. doi: 10.11648/j.crj.20231104.13
AMA Style
Juan D. A Study of Symptom Experience of Hepatocellular Carcinoma Patients After Hepatic Arterial Infusion Chemotherapy Surgery. Cancer Res J. 2023;11(4):136-141. doi: 10.11648/j.crj.20231104.13
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.crj.20231104.13,
author = {Deng Juan},
title = {A Study of Symptom Experience of Hepatocellular Carcinoma Patients After Hepatic Arterial Infusion Chemotherapy Surgery},
journal = {Cancer Research Journal},
volume = {11},
number = {4},
pages = {136-141},
doi = {10.11648/j.crj.20231104.13},
url = {https://doi.org/10.11648/j.crj.20231104.13},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.crj.20231104.13},
abstract = {Background: Hepatocellular carcinoma is the 2nd leading cause of cancer death among Chinese residents. Patients with cancer simultaneously experience multiple symptoms. Most of the current studies on patients with advanced hepatocellular carcinoma focus on the treatment effect, or focus on a single symptom, with less attention to the management of symptom clusters in patients. Objectives: The aim of this research is to explore the symptom experience of hepatocellular carcinoma patients after hepatic arterial infusion chemotherapy surgery and the Relationship between each symptom experience and total number of patient symptoms. Methods: A symptom Assessment Questionnaire for Patients undergoing Hepatic Arterial Infusion Chemotherapy (HAIC) was administered to a sample of 278 patients with hepatocellular carcinoma at advanced stages. Data were analyzed using descriptive statistics, Pearson correlation, and regression analyses. Results: The most striking result to emerge from the data is that the most severe symptoms in patients after HAIC surgery were Poor sleep and Decreased appetite. And presence of psychological suffering, pain, gastrointestinal discomfort, and bad mood may cause patients to develop more symptoms. Conclusions: Patients with hepatoma after HAIC surgery concurrently experienced multiple symptoms of discomfort. We should pay more attention to the symptomatic experience of these patients. A further study with more focus on the management of the most common and comorbid multiple symptoms to reduce symptoms and improve quality of life in patients with hepatocellular carcinoma is therefore suggested.
},
year = {2023}
}
TY - JOUR T1 - A Study of Symptom Experience of Hepatocellular Carcinoma Patients After Hepatic Arterial Infusion Chemotherapy Surgery AU - Deng Juan Y1 - 2023/12/08 PY - 2023 N1 - https://doi.org/10.11648/j.crj.20231104.13 DO - 10.11648/j.crj.20231104.13 T2 - Cancer Research Journal JF - Cancer Research Journal JO - Cancer Research Journal SP - 136 EP - 141 PB - Science Publishing Group SN - 2330-8214 UR - https://doi.org/10.11648/j.crj.20231104.13 AB - Background: Hepatocellular carcinoma is the 2nd leading cause of cancer death among Chinese residents. Patients with cancer simultaneously experience multiple symptoms. Most of the current studies on patients with advanced hepatocellular carcinoma focus on the treatment effect, or focus on a single symptom, with less attention to the management of symptom clusters in patients. Objectives: The aim of this research is to explore the symptom experience of hepatocellular carcinoma patients after hepatic arterial infusion chemotherapy surgery and the Relationship between each symptom experience and total number of patient symptoms. Methods: A symptom Assessment Questionnaire for Patients undergoing Hepatic Arterial Infusion Chemotherapy (HAIC) was administered to a sample of 278 patients with hepatocellular carcinoma at advanced stages. Data were analyzed using descriptive statistics, Pearson correlation, and regression analyses. Results: The most striking result to emerge from the data is that the most severe symptoms in patients after HAIC surgery were Poor sleep and Decreased appetite. And presence of psychological suffering, pain, gastrointestinal discomfort, and bad mood may cause patients to develop more symptoms. Conclusions: Patients with hepatoma after HAIC surgery concurrently experienced multiple symptoms of discomfort. We should pay more attention to the symptomatic experience of these patients. A further study with more focus on the management of the most common and comorbid multiple symptoms to reduce symptoms and improve quality of life in patients with hepatocellular carcinoma is therefore suggested. VL - 11 IS - 4 ER -
Department Minimally Invasive Intervention II, Center of Medical Imaging and Minimally Invasive Therapy, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P. R China
Information